Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?

AME Clinical Trials Review(2024)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要